ESSENCE
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients with Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or with Severe Hypertriglyceridemia
- Stage
- klaar
- Medicine
- Olezarsen
- Population
- ASCVD
- Phase
- III
- First Patient In
- 23 June 2023
- Last Patient In
- 14 February 2024
- Last Patient Last Visit
- 28 May 2025